Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma

G.V. Long, A. Hauschild, M. Santinami, V. Atkinson, M. Mandal, V. Chiarion-Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, D. Schadendorf, T. Lesimple, R. Plummer, R. Ji, P. Zhang, B. Mookerjee, J. LegosR. Kefford, R. Dummer, J.M. Kirkwood

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib at a dose of 150 mg twice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months. The primary end point was relapse-free survival. Secondary end points included overall survival, distant metastasis-free survival, freedom from relapse, and safety. RESULTS At a median follow-up of 2.8 years, the estimated 3-year rate of relapse-free survival was 58% in the combination-Therapy group and 39% in the placebo group (hazard ratio for relapse or death, 0.47; 95% confidence interval [CI], 0.39 to 0.58; P
Original languageEnglish
Pages (from-to)1813-1823
Number of pages11
JournalNew England Journal of Medicine
Volume377
Issue number19
DOIs
Publication statusPublished - Nov 9 2017

Fingerprint Dive into the research topics of 'Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma'. Together they form a unique fingerprint.

Cite this